The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis.
about
From proprotein convertase subtilisin/kexin type 9 to its inhibition: state-of-the-art and clinical implicationsPCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic eraWhat is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysisBiology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering.No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies.Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.An evaluation of alirocumab for the treatment of hypercholesterolemia.Proprotein convertase subtilisin/kexin type 9 (PCSK9) and metabolic syndrome: insights on insulin resistance, inflammation, and atherogenic dyslipidemia.Association of Lipid Fractions With Risks for Coronary Artery Disease and DiabetesPCSK9 and carbohydrate metabolism: A double-edged sword.Using Human 'Experiments of Nature' to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors.Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials.[PCSK9 inhibitors in hypercholesterolemia. New hope for patients with diabetes mellitus?].
P2860
Q26741078-87674F0B-5E81-4A55-92E4-98A82BDF3A24Q28073656-03E8ED30-1F40-42E0-90DA-C12CD846F4F1Q33792275-6E582DB5-3908-4575-A108-51D8065876D9Q34536594-735F380C-4049-44DB-89BD-36D0983FAB4CQ37367952-50876464-1CC5-4918-9EE6-EF4D06DBEBF8Q37744428-D6C0344C-8D46-4584-8040-C72D171387C5Q38632198-F6121C0A-0108-487A-8F89-DDAB0A03474FQ38796312-31379F2F-9C4C-42EA-90E1-423F364F36BDQ39529136-69FB7DE4-C4C7-4069-A2E4-96F61EEF1F6FQ42333207-64260CDD-4791-44E3-B896-DA314AB9D6AAQ47353483-96BB372A-DCEE-4EC3-9394-8DBF120F252CQ48254766-2330138F-166F-46F3-9A7F-78A5FDE6924BQ53204305-A5C960D3-F70D-4828-8D8E-FA695458502C
P2860
The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis.
@en
type
label
The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis.
@en
prefLabel
The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis.
@en
P2093
P2860
P50
P1433
P1476
The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis.
@en
P2093
Bertrand Cariou
Beverley Balkau
Cédric Le May
DESIR study group
Guillaume Charpentier
Sylvia Franc
P2860
P2888
P304
P356
10.1007/S00125-015-3659-8
P577
2015-06-07T00:00:00Z